TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24861159

Group type: EXPERIMENTAL
Intervention: Phonological therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Articulation therapy
Number of subjects: 14
Study: 22572080

Group type: EXPERIMENTAL
Intervention: X6FFF photon beam
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: X10FFF photon beam
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: X10 photon beam
Number of subjects: 7

Group type: COMPARATOR
Intervention: Flattened beams (X6, X10)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FFF beams (X6FFF, X10FFF)
Number of subjects: 7
Study: 20199367

Group type: EXPERIMENTAL
Intervention: Rituximab (group 1, 13 patients)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: No rituximab (group 2, 26 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 39
Study: 18827302

Group type: EXPERIMENTAL
Intervention: Guided self-instructions combined with email contact
Number of subjects: 171

Group type: COMPARATOR
Intervention: Waiting-list condition
Number of subjects: 171
Study: 15939139

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (standard administration)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and folinic acid plus carboplatin (chronomodulated administration)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, standard administration)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with 5-fluorouracil and folinic acid (without carboplatin, chronomodulated administration)
Number of subjects: 37
Study: 12847071

Group type: EXPERIMENTAL
Intervention: EH+
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EH-
Number of subjects: 36

Group type: COMPARATOR
Intervention: NT
Number of subjects: 36
Study: 11783243

Group type: EXPERIMENTAL
Intervention: Composite salviae dropping pill (CSDP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 70
Study: 8676423

Group type: EXPERIMENTAL
Intervention: Augmenting DO2 with fluids, blood, and vasopressors
Number of subjects: 15
Study: 1930035

Group type: EXPERIMENTAL
Intervention: 15 minute oxytocin dose escalation
Number of subjects: 224

Group type: COMPARATOR
Intervention: 30 minute oxytocin dose escalation
Number of subjects: 224
Study: 3883697

Group type: EXPERIMENTAL
Intervention: Alaproclate 200 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31874882

Group type: EXPERIMENTAL
Intervention: Periacetabular osteotomy (PAO) followed by usual care and progressive resistance training (PRT) for 8 months after 4 months of usual care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Progressive resistance training (PRT) only for 12 months
Number of subjects: 96
Study: 30177338

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) of CTO (n=77)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No-CTO PCI (n=81)
Number of subjects: 158
Study: 27428186

Group type: EXPERIMENTAL
Intervention: Intensive treatment with methotrexate, leflunomide, and hydroxychloroquine for up to 36 weeks
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Tapering DMARDs treatment after achieving remission (DAS28 ≤ 2.6) and low HAQ (≤ 0.5)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Leflunomide monotherapy
Number of subjects: 346
Study: 25414593

Group type: EXPERIMENTAL
Intervention: Combined psoas compartment-sciatic nerve block (PCSNB) using 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine and iliac crest block with 5 mL of the same solution.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia (CSA) using 2.5 mg of isobaric bupivacaine 0.5%, with additional doses if sensory block did not reach T12.
Number of subjects: 70
Study: 22692125

Group type: EXPERIMENTAL
Intervention: Passive static stretching (PSS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Active dynamic warm-up (AD)
Number of subjects: 17
Study: 21193005

Group type: EXPERIMENTAL
Intervention: Test product
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 14
Study: 18399947

Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg twice daily for 3 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17176790

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 28
Study: 14522414

Group type: EXPERIMENTAL
Intervention: Enalapril pre-treatment for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enalapril 2 hours before LPS infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pre-treatment for 5 days
Number of subjects: 30
Study: 10951609

Group type: EXPERIMENTAL
Intervention: Agoraphobic patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 34
Study: 8776360

Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone dipropionate) + tretinoin 0.1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone dipropionate)
Number of subjects: 20
Study: 1623802

Group type: EXPERIMENTAL
Intervention: T + E (Terbutaline + Enalapril 10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T + S (Terbutaline + Spironolactone 100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: T (Terbutaline alone)
Number of subjects: 20
Study: 6098505

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31491444

Group type: EXPERIMENTAL
Intervention: N35 (35 min nap opportunity)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N45 (45 min nap opportunity)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N25 (25 min nap opportunity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: N0 (no nap opportunity)
Number of subjects: 20
Study: 30007061

Group type: EXPERIMENTAL
Intervention: Computer-controlled pressure pain threshold as test-stimulus and tourniquet cuff as conditioning stimulus
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Manual pressure algometry and cold water immersion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Various CPM protocols
Number of subjects: 26
Study: 26755688

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 14
Study: 24002924

Group type: EXPERIMENTAL
Intervention: Hands-on training for the Lachman test (15 minutes with lightly embalmed cadaver)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture-only training on knee anatomy and Lachman test
Number of subjects: 0
Study: 22005892

Group type: EXPERIMENTAL
Intervention: LITA in patients with intermediate-grade stenosis
Number of subjects: 142

Group type: COMPARATOR
Intervention: LITA in patients with high-grade stenosis
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: LITA lumen area in patients with intermediate-grade stenosis
Number of subjects: 142

Group type: COMPARATOR
Intervention: LITA lumen area in patients with high-grade stenosis
Number of subjects: 142
Study: 19450896

Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha (IFN-alpha)
Number of subjects: 21
Study: 17822189

Group type: EXPERIMENTAL
Intervention: Conjunctival-limbal autografting
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mitomycin C 0.02% for two minutes
Number of subjects: 60
Study: 16280432

Group type: EXPERIMENTAL
Intervention: Glucose solution (300 mL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water (control, 300 mL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Aspartame solution (300 mL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Maltodextrin solution (300 mL)
Number of subjects: 5
Study: 12228789

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sibutramine (both doses)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 184
Study: 10321487

Group type: EXPERIMENTAL
Intervention: Implicit processing in neglect patient (JS) using a flanker task with coloured letters.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Controls in the flanker task.
Number of subjects: 1
Study: 8708979

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (20 mL single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Algitec Suspension (20 mL single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Algitec Suspension
Number of subjects: 12
Study: 2196360

Group type: EXPERIMENTAL
Intervention: APDT vaccine
Number of subjects: 75

Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 75
Study: 424686

Group type: EXPERIMENTAL
Intervention: Jejuno-ileal bypass operation
Number of subjects: 5
Study: 30620643

Group type: EXPERIMENTAL
Intervention: Fast bolus delivery (30 s using Animas IR2020 pump)
Number of subjects: 20
Study: 28145409

Group type: EXPERIMENTAL
Intervention: Active dTMS (20 sessions over the left dorsolateral prefrontal cortex, H1-coil, 55 18 Hz 2 s 120% MT trains)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham dTMS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Active dTMS
Number of subjects: 50
Study: 26225442

Group type: EXPERIMENTAL
Intervention: Supervision program (announcements of inspections, site visits, individualized reports)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control care groups
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Supervision program
Number of subjects: 356
Study: 23359664

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System for Adherence (MESA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Active nutrition and physical activity control
Number of subjects: 76
Study: 21987967

Group type: EXPERIMENTAL
Intervention: Technology-assisted relaxation training (using a video clip of virtual reality relaxing scenes)
Number of subjects: 60
Study: 20205027

Group type: EXPERIMENTAL
Intervention: Persuasive message advocating smoking cessation
Number of subjects: 254

Group type: COMPARATOR
Intervention: No-information control condition
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Follow-ups at 2 and 8 months
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Point prevalence seven-day quitting
Number of subjects: 254
Study: 16603797

Group type: EXPERIMENTAL
Intervention: Jaeger Masterlab bodyplethysmograph, Pneumoscreen pneumotachograph, Masterscreen CS‐FRC, Masterlab CompactTransfer
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fixed flow generator
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Wave form generator
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: In vivo study
Number of subjects: 59
Study: 12677622

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of IV lidocaine (group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1 mL/kg of IV isotonic saline (group C)
Number of subjects: 40
Study: 11149431

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 9175666

Group type: EXPERIMENTAL
Intervention: Maternal serum beta-HCG level in women with fetal growth retardation (n = 31)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Maternal serum beta-HCG level in women with normal growth (n = 26)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Correlation between maternal serum beta-HCG level and umbilical artery systolic/diastolic ratio
Number of subjects: 57
Study: 8400327

Group type: EXPERIMENTAL
Intervention: High levels of tumour cyclic AMP binding proteins (> 8 pmol/mg cytosol protein)
Number of subjects: 0
Study: 2418713

Group type: EXPERIMENTAL
Intervention: Formaldehyde modified ragweed allergen (allergoid) 10,710 PNU pre-seasonally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formaldehyde modified ragweed allergen (allergoid)
Number of subjects: 20
Study: 29669667

Group type: EXPERIMENTAL
Intervention: GSP301 (olopatadine 665 μg - mometasone 50 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OLO-sponsor (olopatadine 665 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OLO (FDA approved olopatadine 665 μg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: GSP301
Number of subjects: 30

Group type: COMPARATOR
Intervention: OLO-sponsor
Number of subjects: 30

Group type: COMPARATOR
Intervention: OLO
Number of subjects: 30
Study: 27010995

Group type: EXPERIMENTAL
Intervention: Sitting on stability balls for 90 minutes/day, 5 days/week for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group sat on their usual chair for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sitting on stability balls
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ball-sitting
Number of subjects: 90
Study: 24913451

Group type: EXPERIMENTAL
Intervention: Version 2 (V2) of the e-learning resource
Number of subjects: 0

Group type: COMPARATOR
Intervention: Version 1 (V1) of the e-learning resource
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both versions (V1 and V2)
Number of subjects: 0
Study: 22823966

Group type: EXPERIMENTAL
Intervention: High-repetitive single limb exercise (HRSLE) training with elastic bands, 60 minutes, three times/week for 8 weeks combined with four sessions of 60 minutes patient education.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient education alone.
Number of subjects: 0
Study: 20413741

Group type: EXPERIMENTAL
Intervention: Treadmill walking with body weight support (up to 30 minutes per day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Overground walking (up to 30 minutes per day)
Number of subjects: 126
Study: 18483167

Group type: EXPERIMENTAL
Intervention: Essential AA supplementation (AA group, n = 7)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance training with AA given 3 h after training (RT group, n = 12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance training with AA given 5 min before training (AART group, n = 12)
Number of subjects: 31

Group type: COMPARATOR
Intervention: AA group (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined resistance training with AA supplementation (RT and AART groups)
Number of subjects: 31
Study: 15587882

Group type: EXPERIMENTAL
Intervention: New priority X-ray method for examining the large bowel (one-stage double contrasting)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional irrigoscopy and classical double contrasting
Number of subjects: 150
Study: 11434120

Group type: EXPERIMENTAL
Intervention: Preoperative epidural blockade
Number of subjects: 100
Study: 9209769

Group type: EXPERIMENTAL
Intervention: Episodic cluster headache patients
Number of subjects: 27
Study: 7811150

Group type: EXPERIMENTAL
Intervention: Oral administration of delayed action mexiletine
Number of subjects: 77
Study: 3658285

Group type: EXPERIMENTAL
Intervention: 25-mg 17 beta-estradiol pellets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50-mg 17 beta-estradiol pellets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25-mg and 50-mg 17 beta-estradiol pellets
Number of subjects: 12
Study: 31317627

Group type: EXPERIMENTAL
Intervention: 4 mL of 75% oral sucrose (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (sterilised water) (n = 20)
Number of subjects: 40
Study: 29068099

Group type: EXPERIMENTAL
Intervention: Ciclosporin 50 mg/mL solution for injection administered subcutaneously for 60 days, with initial doses ranging from 2.5 mg/kg once daily to every other day, and 5 mg/kg once daily to every other day.
Number of subjects: 11
Study: 27484224

Group type: EXPERIMENTAL
Intervention: Iloprost (1 ng/kg/min) infusion for 48 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iloprost with blood pressure target of 65 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iloprost with blood pressure target of 75 mmHg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with blood pressure target of 65 mmHg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with blood pressure target of 75 mmHg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 40
Study: 25400947

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg orally every 12 hours for at least 2 days
Number of subjects: 600

Group type: COMPARATOR
Intervention: Magnesium sulfate 4 grams intravenously
Number of subjects: 600
Study: 22494852

Group type: EXPERIMENTAL
Intervention: Mental retrieval of exposure session
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition (recall of everyday activities)
Number of subjects: 72
Study: 21168619

Group type: EXPERIMENTAL
Intervention: Standard dose of cyclosporine (blood cyclosporine C2, 800-1500 ng/mL) with MMF and standard doses of corticosteroids.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low dose of cyclosporine (blood cyclosporine C2, 450-800 ng/mL) with MMF plus low doses of corticosteroids after induction 48 hours before surgery.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 80
Study: 18212330

Group type: EXPERIMENTAL
Intervention: Skills-demands compatibility manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16725396

Group type: EXPERIMENTAL
Intervention: Calcium-vitamin-D3-fortified milk (1000 mg/day calcium and 800 IU/day vitamin D3)
Number of subjects: 111
Study: 12555214

Group type: EXPERIMENTAL
Intervention: Thromboembolic events (TE)
Number of subjects: 183

Group type: COMPARATOR
Intervention: No thromboembolic events (Control)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Primary TE
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Recurrent TE
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Secondary TE
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TE patients
Number of subjects: 183
Study: 11040177

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (0.75‐1 mg x kg(‐1) x day(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heparin (continuous infusion)
Number of subjects: 25
Study: 9222576

Group type: EXPERIMENTAL
Intervention: 10-session, learner-centred, small group CME program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (10 control subjects)
Number of subjects: 15
Study: 1350734

Group type: EXPERIMENTAL
Intervention: Polyanhydrides as bioerodible polymers for drug delivery applications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyanhydride-based drug delivery treatment
Number of subjects: 0
Study: 2981616

Group type: EXPERIMENTAL
Intervention: Levonantradol (1 mg every 4 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delta-9-tetrahydrocannabinol (THC) (15 mg every 4 hours)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Levonantradol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 26
Study: 30736764

Group type: EXPERIMENTAL
Intervention: CST with specific, structured and behavior‐orientated feedback (CST-behav)
Number of subjects: 66

Group type: COMPARATOR
Intervention: General, experience‐orientated feedback (CST-exp)
Number of subjects: 66
Study: 29568986

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 103
Study: 27135460

Group type: EXPERIMENTAL
Intervention: Simulation training (1 hour of total instruction during a 3-month period)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 22
Study: 25209188

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) intervention
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2160
Study: 23062747

Group type: EXPERIMENTAL
Intervention: Multi-component programme with clinical, educational and organizational procedures including primary care nurses as case-managers
Number of subjects: 338
Study: 20214714

Group type: EXPERIMENTAL
Intervention: Sexual education group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsexual education group
Number of subjects: 100
Study: 18068515

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 15753149

Group type: EXPERIMENTAL
Intervention: Selenium (200 mcg l-selenomethionine)
Number of subjects: 32400

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg of racemic alpha-tocopheryl)
Number of subjects: 32400

Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E (combined)
Number of subjects: 32400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32400
Study: 11728984

Group type: EXPERIMENTAL
Intervention: EPO 50 U/kg by subcutaneous injection 3 times per week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EPO 50 U/kg IV injection and AG 200 mg every other day by mouth
Number of subjects: 21

Group type: COMPARATOR
Intervention: EPO 50 U/kg IV injection and placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care without EPO
Number of subjects: 21
Study: 9684134

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ampicillin plus Gentamicin
Number of subjects: 22
Study: 8150356

Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with 4 litres/minute for five minutes before sedation, followed by continuous oxygen administration.
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pre-oxygenation.
Number of subjects: 50
Study: 3337037

Group type: COMPARATOR
Intervention: Diet without exercise (DO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet plus weight training (DPE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weight training without diet (EO)
Number of subjects: 40
Study: 28917619

Group type: EXPERIMENTAL
Intervention: 0.05% Chlorhexidine Gluconate (CHG)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sterile Water (Control)
Number of subjects: 111